Residency · Residency · Pediatrics

Pediatric Asthma: Diagnosis and Stepwise Management

Overview

Asthma is the most common chronic disease of childhood, affecting approximately 8% of US children. It is characterized by reversible airway obstruction, chronic airway inflammation, and bronchial hyperresponsiveness. Diagnosis in children under 5 years is clinical (spirometry is not reliable at this age), while children 6 and older can undergo spirometry with bronchodilator reversibility testing. Common phenotypes include allergic asthma (the most common in children), exercise-induced bronchoconstriction, and viral-triggered wheezing. Significant health disparities exist, with Black and Puerto Rican children experiencing disproportionately higher prevalence, ED visits, and mortality.

Pathophysiology

The early phase response occurs within minutes as IgE-mediated mast cell degranulation releases histamine, leukotrienes, and prostaglandins causing bronchoconstriction. The late phase (4-8 hours later) involves eosinophilic and lymphocytic infiltration, mucus hypersecretion, and airway edema. Chronic remodeling develops over time with subepithelial fibrosis, smooth muscle hypertrophy, and goblet cell hyperplasia. Key inflammatory mediators include IL-4, IL-5, and IL-13 (the Th2 pathway) along with leukotrienes C4, D4, and E4.

Diagnosis

Children 6 Years and Older

Spirometry showing an FEV1/FVC ratio below the lower limit of normal establishes obstruction. Bronchodilator reversibility (12% or greater improvement in FEV1 after SABA administration) confirms the diagnosis. When spirometry is normal but asthma is suspected, a methacholine challenge with PC20 less than 4 mg/mL supports the diagnosis. Peak flow variability greater than 20% diurnally over 2 weeks is an additional diagnostic criterion.

Children Under 5 Years

Diagnosis is clinical and based on pattern recognition. The Modified Asthma Predictive Index (mAPI) helps predict which wheezing preschoolers will develop persistent asthma. Major criteria include parental asthma, atopic dermatitis, and allergic sensitization to aeroallergens. Minor criteria include allergic sensitization to food, wheezing apart from colds, and eosinophilia of 4% or greater. Recurrent wheezing (3 or more episodes per year) with a positive mAPI indicates a high likelihood of asthma.

Differential Diagnosis

Important alternative diagnoses include foreign body aspiration, vocal cord dysfunction, vascular ring, tracheomalacia, cystic fibrosis, primary ciliary dyskinesia, bronchopulmonary dysplasia, immunodeficiency, and GERD.

<image>Modified Asthma Predictive Index (mAPI) decision tree showing major and minor criteria for predicting persistent asthma in preschool-age wheezers, with sensitivity and specificity values</image>

Severity Classification and Stepwise Therapy (NAEPP EPR-4)

Classification (Before Treatment)

Asthma severity is classified before initiating treatment. Intermittent asthma involves symptoms 2 or fewer days per week, 2 or fewer nights per month, normal FEV1, and 1 or fewer exacerbations per year. Mild persistent involves symptoms more than 2 days per week but not daily with 3-4 nights per month affected. Moderate persistent involves daily symptoms, 1 or more nights per week, and FEV1 60-80%. Severe persistent involves symptoms throughout the day and nightly with FEV1 below 60%.

Stepwise Approach (Ages 5-11 and 12 and Older)

Step 1 uses PRN SABA alone for intermittent asthma. Step 2 adds low-dose inhaled corticosteroids (ICS) daily as the preferred option, with leukotriene receptor antagonists (montelukast) as an alternative. Step 3 combines low-dose ICS with a long-acting beta-agonist (LABA) as preferred, or medium-dose ICS. Step 4 uses medium-dose ICS plus LABA. Step 5 escalates to high-dose ICS plus LABA with consideration of add-on tiotropium, anti-IgE (omalizumab), anti-IL5, or anti-IL4/13 biologics. Step 6 adds oral corticosteroids and biologic therapy to high-dose ICS plus LABA.

Stepwise Approach (Ages 0-4)

For the youngest patients, Step 1 uses PRN SABA. Step 2 adds low-dose ICS (preferred). Step 3 escalates to medium-dose ICS. Step 4 combines medium-dose ICS with LTRA or specialist referral. Notably, LABAs are not FDA-approved for children under 4 years.

Key Controller Medications

Inhaled corticosteroids are the cornerstone of persistent asthma therapy, with low-dose examples including fluticasone 88 mcg/day and budesonide 0.25-0.5 mg nebulized. Growth velocity should be monitored as there is a potential 0.5-1 cm reduction in final adult height. Long-acting beta-agonists (salmeterol, formoterol) must never be used as monotherapy. Montelukast now carries an FDA boxed warning for neuropsychiatric events (issued 2020). Tiotropium (Spiriva Respimat) is available as add-on therapy for ages 6 and older with uncontrolled asthma. Biologic therapies include omalizumab (anti-IgE, ages 6 and older), dupilumab (anti-IL4R, ages 6 and older), and mepolizumab (anti-IL5, ages 6 and older).

<image>NAEPP EPR-4 stepwise approach diagram for asthma management in children aged 5-11 years showing six treatment steps from PRN SABA alone to high-dose ICS-LABA with oral corticosteroids and biologic therapy, with arrows indicating step-up and step-down decisions</image>

Acute Asthma Exacerbation Management

Assessment

Assessment includes respiratory rate, oxygen saturation, accessory muscle use, ability to speak, and wheeze quality. PEF (if the patient can perform it) categorizes severity: greater than 80% is mild, 50-80% moderate, and less than 50% severe. The "quiet chest" — minimal wheezing with severe obstruction — indicates critical airflow limitation and must not be mistakenly reassuring.

Emergency Department Management

Oxygen is administered to maintain SpO2 of 92% or greater. Albuterol is given nebulized (2.5-5 mg) or via MDI (4-8 puffs) every 20 minutes for 3 treatments, then hourly. Ipratropium bromide (0.25-0.5 mg nebulized) is added with the first 3 albuterol treatments for severe exacerbations. Systemic corticosteroids are given as either dexamethasone 0.6 mg/kg (maximum 16 mg) for 1-2 doses or prednisone/prednisolone 1-2 mg/kg/day for 3-5 days. Dexamethasone is increasingly preferred for its superior adherence and equivalent outcomes with fewer doses and less vomiting.

For severe exacerbations not responding to initial therapy, magnesium sulfate at 25-75 mg/kg IV (maximum 2 g) is administered. Continuous albuterol nebulization at 0.5 mg/kg/hr (maximum 20 mg/hr) is used for severe or refractory cases. Epinephrine 0.01 mg/kg IM is given for impending respiratory failure. IV terbutaline is considered in the ICU for status asthmaticus.

Disposition Criteria

Discharge is appropriate with sustained improvement, SpO2 of 92% or greater on room air, and PEF of 70% or greater. Admission is indicated for persistent respiratory distress, SpO2 below 92%, PEF below 50%, or history of ICU admissions.

Asthma Action Plans

The traffic light system organizes home management into green (well-controlled, continue daily medications), yellow (worsening symptoms, increase SABA frequency, consider doubling ICS, start oral steroids per plan), and red (severe symptoms, administer SABA and oral steroids, go to ED) zones. Written plans should be provided to families, school nurses, and daycares.

SMART Therapy (Single Maintenance and Reliever Therapy)

SMART uses ICS-formoterol as both the daily controller and PRN rescue inhaler, reducing exacerbations compared to traditional ICS plus PRN SABA. The EPR-4 update recommends ICS-formoterol PRN as preferred therapy at Steps 1-2 for ages 12 and older. Budesonide-formoterol received FDA approval in 2023 for ages 12 and older. Data in children 4-11 years is emerging but limited.

<image>Asthma action plan template using traffic light system with green (well-controlled), yellow (caution with increased symptoms), and red (medical alert) zones showing medication adjustments and criteria for emergency care at each level</image>

<image>Comparison of traditional asthma management (daily ICS controller plus PRN SABA rescue) versus SMART therapy (single ICS-formoterol inhaler for both maintenance and rescue), showing mechanism of action, exacerbation reduction data, and current age-based recommendations</image>

Clinical Pearls

Montelukast carries an FDA boxed warning for neuropsychiatric events including suicidal ideation and should be used as a second-line agent only with appropriate family counseling. Dexamethasone (1-2 doses) is as effective as 5-day prednisone for mild-to-moderate exacerbations with better adherence and less vomiting. Normal spirometry does not exclude asthma because symptoms may be intermittent; consider methacholine challenge or an empiric trial of therapy. Inhaler technique should be assessed at every visit because poor technique is the most common cause of "uncontrolled" asthma. Environmental control measures (dust mite covers, HEPA filters, smoking cessation) are essential but often underemphasized. In a wheezing child not responding to bronchodilators, the diagnosis should be reconsidered (foreign body, vocal cord dysfunction, cardiac disease).

Key Controversy: ICS-Formoterol PRN as SMART in Children Under 12

Multiple adult and adolescent trials (SYGMA, Novel START) demonstrate superiority of PRN ICS-formoterol over PRN SABA alone. Pediatric data for ages 4-11 is limited, and current EPR-4 recommends SMART only for ages 12 and older. Concerns include formoterol being a LABA with historical safety concerns in pediatrics (though the FDA boxed warning has since been removed based on large safety trials), and practical barriers with budesonide-formoterol inhaler dosing potentially not optimized for young children. The likely future direction is extension of SMART to younger ages as pediatric trial data accumulates.

References

• National Asthma Education and Prevention Program (NAEPP). EPR-4: Expert Panel Report 4 — Management of Asthma. NHLBI. 2020 Focused Updates.
• Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2023.
• O'Byrne PM, et al. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma (SYGMA Trials). N Engl J Med. 2018;378(20):1865-1876.
• Normansell R, et al. Inhaled Corticosteroids in Combination with Long-Acting Beta2-Agonists vs. Higher Doses of Inhaled Corticosteroids in Children. Cochrane Database Syst Rev. 2015;(7):CD010958.
• Castro-Rodriguez JA, et al. Asthma Predictive Index: A Very Useful Tool for Predicting Asthma in Young Children. J Allergy Clin Immunol. 2010;126(2):212-216.
• Keeney GE, et al. Dexamethasone for Acute Asthma Exacerbations in Children. Pediatrics. 2014;133(3):493-499.

Read this lecture as Markdown